MapLight Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Dec 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Dec 4, 2025
MPLT$7.44+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(81,604) | $(56,351) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 438 | 507 |
| Stock-based compensation expense | 485 | 866 |
| Net amortization of premiums and accretion of discounts on investments | (660) | (1,332) |
| Common stock issued to NeuroSolis | 496 | — |
| Non-cash lease expense | 644 | 539 |
| Loss from equity method investment | — | 986 |
| Loss from disposal and write-off of equipment | 7 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (10,774) | (882) |
| Accounts payable | 491 | (1,188) |
| Accrued expenses | 1,775 | 964 |
| Operating lease liability | (573) | (477) |
| Deferred grant earnings | (2,033) | (959) |
| Net cash used in operating activities | (91,308) | (57,327) |
| Cash flows from investing activities | ||
| Purchases of short-term and long-term investments | (142,057) | (125,018) |
| Maturities of marketable debt securities | 61,500 | 12,500 |
| Purchases of property and equipment | (97) | (664) |
| Net cash used in investing activities | (80,654) | (113,182) |
| Cash flows from financing activities | ||
| Payments of deferred financing costs | (1,127) | (2,173) |
| Proceeds from issuance of Series C redeemable convertible preferred stock and preferred stock purchase right, net of issuance costs | — | 119,956 |
| Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs | 198,870 | — |
| Proceeds from exercise of stock options | 112 | 272 |
| Net cash provided by financing activities | 197,855 | 118,055 |
| Increase (decrease) in cash, cash equivalents, and restricted cash | 25,893 | (52,454) |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,460 | 80,003 |
| Cash, cash equivalents, and restricted cash at end of period | $64,353 | $27,549 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Right of use asset obtained in exchange for operating lease liability | $— | $1,485 |
| Proceeds from exercise of stock options included in prepaid expenses and other current assets | $79 | $— |
| Purchase of property and equipment included in accounts payable and accrued expenses | $— | $60 |
| Deferred financing costs included in accounts payable and accrued expenses | $2,325 | $769 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.